5 August 2025
ASX Release

# Peer-Reviewed Case Study for CannEpil® in Treatment-Resistant Epilepsy

## HIGHLIGHTS

- Peer-reviewed case report published in International Journal of Clinical Medicine & Case Reports
- Demonstrates clinical benefits of CannEpil® in a pediatric patient with Lennox-Gastaut Syndrome
- Significant reduction in seizure frequency and severity following treatment
- Improved quality of life and cognitive function reported
- Study affirms CannEpil®'s pharmaceutical-grade formulation advantages over botanical extracts

Argent BioPharma Limited (**ASX: RGT**) is pleased to inform shareholders that a new independent, peer-reviewed case study has been published in the International Journal of Clinical Medicine & Case Reports, highlighting the therapeutic potential of CannEpil® in managing treatment-resistant epilepsy.

The article, titled "Management of Lennox-Gastaut Syndrome with a CBD/THC Isolate Combination" (DOI: 10.46998/IJCMCR.2025.54.001331), details the successful treatment of a pediatric patient with Lennox-Gastaut Syndrome using CannEpil®, a proprietary CBD/THC isolate formulation produced under EU-GMP standards by Argent BioPharma.

The case study, authored by Argent's VP of Medical Development Dr. Jonathan Grunfeld and Medical researcher Dr. Jasna Jarc, describes a dramatic improvement in seizure control, cognitive ability, and overall quality of life. Notably, the patient experienced:

- Reduced seizure clusters and daily seizure frequency
- Recovery of speech, fine motor control, and independent mobility
- Reintegration into a full-time educational environment

This publication strengthens the growing body of real-world evidence supporting CannEpil®'s use in complex epilepsy syndromes and underscores the benefit of using pharmaceutical-grade isolate combinations over full-spectrum botanical preparations—providing both dosing precision and enhanced safety.

**Dr. Jonathan Grunfeld, VP of Medical Development at Argent BioPharma, stated:**

*"This case exemplifies the transformative impact a rigorously formulated cannabinoid therapy can have on patients for whom standard treatments have failed. CannEpil®'s precision, purity, and clinical consistency are central to its success."*

The full article is available online at: https://ijclinmedcasereports.com/pdf/IJCMCR-CR-01331.pdf

***Science meets protocol. Precision meets care.***

—Ends—

Authorised for release by the board of directors, for further information please contact:


Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com


**About Argent BioPharma**

**Argent BioPharma Ltd. (ASX: RGT)** is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its lead assets, *CannEpil®* and *CimetrA®*, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The company's proprietary delivery technologies enhance penetration across the blood–brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection. With integrated EU-GMP manufacturing, clinical-stage programs, and a unified Neuro-Immune Modulatory platform, Argent BioPharma is advancing a high-impact pipeline that excludes oncology and focuses on urgent unmet needs in CNS and systemic inflammation

Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma

**About CannEpil®:**

CannEpil® is an investigational medicinal product developed by Argent BioPharma as an adjunctive therapy for drug-resistant epilepsy (also known as refractory epilepsy), a condition that affects approximately 30% of all epilepsy patients and represents a major unmet medical need.

CannEpil® aims to reduce seizure frequency, improve quality of life, and enhance patient care through continuous monitoring. It is intended for use in patients who do not respond adequately to existing anti-epileptic treatments.

Originally made available in Australia through the Special Access Scheme (**SAS**), CannEpil® is now accessible for prescription in Ireland, the United Kingdom, and Germany under Early Patient Access Schemes, expanding treatment options in markets where alternative therapies are limited.